Navigation Links
Pharsight Files Application for Nasdaq Capital Market Listing
Date:9/18/2007

MOUNTAIN VIEW, Calif., Sept. 18 /PRNewswire-FirstCall/ -- Pharsight Corporation (OTC Bulletin Board: PHST), a leading provider of software and strategic services for optimizing clinical drug development, today announced that it has filed an application to list its common stock on the Nasdaq Capital Market. The Company will work with Nasdaq to complete the application process.

"This application is an important milestone for Pharsight," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "Three years ago we embarked upon a strategy that we believed would lead to profitable revenue growth and enhanced value for our stockholders. Since that time, we have delivered consistent, positive net income and revenue growth. We believe the successful listing of Pharsight's common stock on the Nasdaq Capital Market will encourage an increase in our valuation, one that is more in-line with companies with similar dynamics and one that more adequately reflects our long-term opportunities for growth."

As part of the Nasdaq application and approval process, the Company must meet certain eligibility criteria. The Company believes it currently meets every eligibility criterion with the exception of a minimum bid price of $4. The Company's stockholders recently approved a reverse stock split, which, once completed, the Company believes will allow it to meet this final requirement.

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight app
'/>"/>

SOURCE Pharsight Corporation
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. Novartis files application with FDA for Zometa
2. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
3. Unfavourable Lipid-Lipoprotein profiles in older adults has been linked to abdominal visceral fat
4. Understanding Gene Profiles Could Help Cure A Resistant Form Of Leukemia In Kids
5. Personality profiles of gamblers and substance abusers are similar
6. NGO Files Pre-Grant Opposition Against Anti-HIV Drug, Combivir
7. Venus Remedies Files 5th International Patent Application
8. Shoaib Akhtar files appeal against ban
9. AIIMS Official Files Complaint Against Venugopal
10. Glaxo Files Cancer Drug For Approval With FDA
11. Nigeria Files New Lawsuit Against Pfizer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2009)...ewswire-USNewswire/ -- Tonight, in a partisan vote...,s version of the government takeover of health ca... in this bill; like the public option, employer an...or elective abortion, which is the most onerous an...vides subsidies for private plans that cover elect...
(Date:11/21/2009)...ey Provisions of Legislation, Continues Push for P...Ill., Nov. 21 With th...rk Affordable Health Care for America Act (H.R. 39...lation forward, Congress has taken decisive steps ...day, AARP hosted an educational forum to discuss t...
(Date:11/21/2009)...ll, president and chief executive officer of the A...following statement regarding the inclusion of cog...ual wellness for Medicare beneficiaries in "T...; that was introduced last night: , ...-- Eric J. Hall, president and chief executive off...
(Date:11/20/2009)...Newswire-USNewswire/ -- The American Academy of A...re reform legislation released this week to contai...ndividual coverage mandate. The actuaries said tha...ze adverse selection stemming from more restrictiv..., "The individual mandate language should be st...
(Date:11/20/2009)...ire-USNewswire/ -- The American Dental Association...ration (FDA) to establish appropriate classificati...oncern about the safety of whitening products that...fessional consultation or examination by a dentist...mically based tooth whitening or bleaching agents ...
Breaking Medicine News(10 mins):Health News:FRC: Senate Votes to Proceed with Abortion Funding Debacle 2Health News:AARP Hosts Rep. Bill Foster In Health Care Reform Forum 2Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 2Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 3Health News:Actuaries to Senate: Strengthen Individual Mandate 2Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2
...SOFT (OCuSOFT,Inc.), a company specializing in oph...lmologists and optometrists, is pleased to announc...., to its Optometric Scientific,Advisory Board. *...d to playing a key role in the center,s developmen...
...ograms and support services in Los ...Lupus Foundation of,America (LFA) and Maybelline(R...ly Foundation hosted the First Annual "Butterflies...than 300,celebrities and guests who helped raise f...
...Dental,Association (ADA) House of Delegates called...nderstand the materials used to create dental fill... ease of placement, durability,and relative costs ...her outlets, the,association wants to ensure its a...
...high Circumference, LAS VEGAS, Oct. 2 Ariana Cos... America to offer Syneron,s VelaShape, the only,FD...inimize cellulite.,VelaShape uses elos technology ...e by almost an inch. Dr. Michael Belfiore of Aria...
...rns based on prostate cancer biopsy were found to ...this measurement could help predict the risk of pr... research published in the October 3 issue of JAMA...umors) of the prostate based on the patterns of pr...
...rch announced the,findings of the latest wave of i...urvey was completed in late June and found that ju...erage are definitely or very likely,to switch to M... switch, general satisfaction with their current,c...
Other Medicine News:Health News:Stars Shine on 'Butterflies Over Hollywood' for Lupus Foundation of America 2Health News:ADA Calls for Scientifically Accurate Patient Brochure Explaining Filling Choices 2Health News:Ariana First to Offer VelaShape in North America 2Health News:Using additional biopsy-scoring data may help determine prostate cancer prognosis 2
(Date:11/20/2009)...0 Smith & Nephew ( S...nnounce the signing of a technology development co...e that may lead to the creation of a fracture fixa...t of the limbs of soldiers who sustain battlefield...esearch Projects Agency (DARPA), the central resea...
(Date:11/19/2009).... 19 BioCryst Pharmaceut...ricing of a public offering of 5,000,000 shares of... gross proceeds of $48.75 million. All of the sha...ffective shelf registration statement previously f... BioCryst has also granted the underwriters a 30-d...
(Date:11/19/2009)...ov. 19 /PRNewswire-Asia/ -- ScinoPharm, a leading ...ts (APIs), announced that its,Tainan facility has ...from,SafeBridge(R) Consultants, Inc. The Certifica...ncy in the safe handling of potent active,pharmace... laboratories and,production areas used for the ma...
Breaking Medicine Technology:Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4BioCryst Announces Pricing of Public Offering of Common Stock 2BioCryst Announces Pricing of Public Offering of Common Stock 3ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2Norman Brinker Honored With 2009 Methodist Health System Folsom Leadership Award 48569 1Norman Brinker Honored With 2009 Methodist Health System Folsom Leadership Award 48569 2Norman Brinker Honored With 2009 Methodist Health System Folsom Leadership Award 48569 3Norman Brinker Honored With 2009 Methodist Health System Folsom Leadership Award 48569 4Haemacure Reports on Strategic Collaboration with Angiotech Pharmaceuticals Inc and Second Quarter 2009 Financial Results 48565 1Haemacure Reports on Strategic Collaboration with Angiotech Pharmaceuticals Inc and Second Quarter 2009 Financial Results 48565 2Haemacure Reports on Strategic Collaboration with Angiotech Pharmaceuticals Inc and Second Quarter 2009 Financial Results 48565 3Haemacure Reports on Strategic Collaboration with Angiotech Pharmaceuticals Inc and Second Quarter 2009 Financial Results 48565 4New Phase 3 Data Continue to Indicate that Wyeths Investigational 13 valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 12578 1New Phase 3 Data Continue to Indicate that Wyeths Investigational 13 valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 12578 2New Phase 3 Data Continue to Indicate that Wyeths Investigational 13 valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 12578 3New Phase 3 Data Continue to Indicate that Wyeths Investigational 13 valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 12578 4New Phase 3 Data Continue to Indicate that Wyeths Investigational 13 valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 12578 5New Phase 3 Data Continue to Indicate that Wyeths Investigational 13 valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 12578 6
...tive Disease Week(R) 2008, NATICK, Mass. and SAN ...: BSX ) today announced results from an,internati...vorable safety,and clinical utility data for its S...s extensive visual access to the biliary tract. Re...Chen, M.D., Division of Gastroenterology,& Hepatol...
...estive Disease Week -, CAMBRIDGE, Mass. and NEW Y...rly Microbia, Inc.) and Forest,Laboratories, Inc. ...data,from a Phase 2b randomized, double-blind, pla...icacy of linaclotide in patients with chronic,cons...t linaclotide met its,primary endpoint. The study ...
Other Medicine Technology:Multi-Center Patient Registry Supports Safety and Clinical Utility of Boston Scientific's SpyGlass(R) Direct Visualization System 2Multi-Center Patient Registry Supports Safety and Clinical Utility of Boston Scientific's SpyGlass(R) Direct Visualization System 3Multi-Center Patient Registry Supports Safety and Clinical Utility of Boston Scientific's SpyGlass(R) Direct Visualization System 4Multi-Center Patient Registry Supports Safety and Clinical Utility of Boston Scientific's SpyGlass(R) Direct Visualization System 5Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 2Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 3Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 4Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 5Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 6
... The Portex® Thermovent® T helps provide p...y patient. It is small and extremely lightweight m...s adults. With a high rate of heat and moisture re...retion retention., ,All HMEs and filters have ISO...
... The Portex® Thermovent® T helps provide p...y patient. It is small and extremely lightweight m...s adults. With a high rate of heat and moisture re...retion retention., ,All HMEs and filters have ISO...
... The Portex® Thermovent® T helps provide p...y patient. It is small and extremely lightweight m...s adults. With a high rate of heat and moisture re...retion retention., ,All HMEs and filters have ISO...
Clear-Therm™ with Flextube
Medicine Products: